Sanford C. Bernstein reaffirmed their market perform rating on shares of GlaxoSmithKline (LON:GSK) in a report released on Wednesday, Analyst Ratings.Net reports. Sanford C. Bernstein currently has a GBX 1,633 ($26.33) price objective on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse reiterated an underperform rating on shares of GlaxoSmithKline in a research note to investors on Tuesday. They now have a GBX 1,500 ($24.18) price target on the stock. Separately, analysts at Deutsche Bank reiterated a buy rating on shares of GlaxoSmithKline in a research note to investors on Wednesday, November 13th. They now have a GBX 1,800 ($29.02) price target on the stock. Finally, analysts at Panmure Gordon downgraded shares of GlaxoSmithKline to a hold rating in a research note to investors on Tuesday, November 12th. They now have a GBX 1,750 ($28.21) price target on the stock, down previously from GBX 1,850 ($29.82). Five analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. GlaxoSmithKline presently has an average rating of Hold and an average target price of GBX 1,616.42 ($26.06).
GlaxoSmithKline (LON:GSK) traded up 0.49% on Wednesday, hitting GBX 1639.50. The stock had a trading volume of 6,164,781 shares. GlaxoSmithKline has a 52-week low of GBX 1323.00 and a 52-week high of GBX 1816.00. The stock’s 50-day moving average is GBX 1599. and its 200-day moving average is GBX 1653.. The company’s market cap is £78.975 billion.
The company also recently declared a dividend, which is scheduled for Thursday, January 9th. Investors of record on Wednesday, November 13th will be given a dividend of $19.00 per share. This represents a yield of 1.15%. The ex-dividend date of this dividend is Wednesday, November 13th.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.